Glargine ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症3

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00483769
(ClinicalTrials.gov)
February 20066/6/2007One Year Glargine Treatment in CFRD Children and AdolescentsOne-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose DerangementsCystic Fibrosis;Glucose Metabolism DisordersDrug: GlargineFederico II UniversityNULLCompleted3 Years20 YearsBoth20Phase 4Italy
2EUCTR2005-002135-27-IT
(EUCTR)
06/07/200528/06/2005Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deteriorationGlargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration Cystic Fibrosis patients with glucose intolerance
MedDRA version: 6.1;Level: PT;Classification code 10011762
Trade Name: LANTUS*SC 5CAR3ML100UI/ML
Product Name: NA
Product Code: NA
INN or Proposed INN: Insulin glargine
ISTITUTO GIANNINA GASLININULLNot RecruitingFemale: yes
Male: yes
Italy
3NCT00222521
(ClinicalTrials.gov)
April 200314/9/2005Insulin Glargine Vs Standard Insulin TherapyComparison of Insulin Glargine Vs Standard Insulin Therapy in CFRD Without Fasting HyperglycemiaCystic Fibrosis Related DiabetesDrug: Glargine insulinUniversity of Minnesota - Clinical and Translational Science InstituteSanofi;Moran, Antoinette, M.D.Completed12 YearsN/ABoth20Phase 3United States